- Home
- GLRE vs BVS Comparison
GLRE vs BVS Comparison
Compare GLRE & BVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | GLRE | BVS |
|---|---|---|
| Founded | 2004 | 2011 |
| Country | Cayman Islands | United States |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 481.5M | 617.1M |
| IPO Year | 2007 | 2016 |
Fundamental Metrics
Financial Performance| Metric | GLRE | BVS |
|---|---|---|
| Price | $18.12 | $10.32 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $14.00 |
| AVG Volume (30 Days) | 243.1K | ★ 416.1K |
| Earning Date | 05-06-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 75.00 | ★ 163.46 |
| EPS | ★ 2.17 | 0.33 |
| Revenue | ★ $729,777,000.00 | $568,087,000.00 |
| Revenue This Year | N/A | $7.52 |
| Revenue Next Year | N/A | $7.06 |
| P/E Ratio | ★ $8.35 | $29.97 |
| Revenue Growth | ★ 4.85 | N/A |
| 52 Week Low | $11.57 | $5.81 |
| 52 Week High | $18.99 | $9.98 |
Technical Indicators
Market Signals| Indicator | GLRE | BVS |
|---|---|---|
| Relative Strength Index (RSI) | 63.65 | 72.84 |
| Support Level | $12.66 | $8.43 |
| Resistance Level | N/A | N/A |
| Average True Range (ATR) | 0.57 | 0.36 |
| MACD | -0.04 | 0.10 |
| Stochastic Oscillator | 58.54 | 87.83 |
Price Performance
Historical ComparisonAbout GLRE Greenlight Capital Re Ltd.
Greenlight Capital Re Ltd offers property and casualty reinsurance. Its customers are property and casualty insurers, and Greenlight takes on some of their risk in exchange for insurance premiums. It operates through one operating segment: property and casualty reinsurance. It generates revenue through premiums from reinsurance on property and casualty business assumed and income from investments.
About BVS Bioventus Inc.
Bioventus Inc is a medical device company focused on developing and commercializing products to relieve pain and address musculoskeletal conditions. The company operates through two reporting segments, U.S. and International, and its product portfolio is organized into three main business areas: Pain Treatments, Surgical Solutions, and Restorative Therapies, offering products such as hyaluronic acid injections for osteoarthritis, peripheral nerve stimulation devices, bone graft substitutes, and ultrasound-based fracture healing therapies.